期刊
MATERIALS
卷 14, 期 14, 页码 -出版社
MDPI
DOI: 10.3390/ma14143909
关键词
tissue engineering; collagen hydrogel; cell delivery; bone regeneration; olfactory ectomesenchyme stem cells
类别
资金
- Iran University of Medical Sciences (IUMS) [98-4-14-16643]
In this study, human olfactory ectomesenchymal stem cells were encapsulated in a collagen hydrogel system and their osteogenic potential was evaluated in vitro and in vivo conditions. The results indicated that the optimal concentration of collagen hydrogel supported high osteogenic differentiation of the stem cells, leading to enhanced bone healing in vivo. These findings suggest that stem cells with suitable carriers could be a promising approach to address clinical bone complications.
For bone tissue engineering, stem cell-based therapy has become a promising option. Recently, cell transplantation supported by polymeric carriers has been increasingly evaluated. Herein, we encapsulated human olfactory ectomesenchymal stem cells (OE-MSC) in the collagen hydrogel system, and their osteogenic potential was assessed in vitro and in vivo conditions. Collagen type I was composed of four different concentrations of (4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL). SDS-Page, FTIR, rheologic test, resazurin assay, live/dead assay, and SEM were used to characterize collagen hydrogels. OE-MSCs encapsulated in the optimum concentration of collagen hydrogel and transplanted in rat calvarial defects. The tissue samples were harvested after 4- and 8-weeks post-transplantation and assessed by optical imaging, micro CT, and H&E staining methods. The highest porosity and biocompatibility were confirmed in all scaffolds. The collagen hydrogel with 7 mg/mL concentration was presented as optimal mechanical properties close to the naive bone. Furthermore, the same concentration illustrated high osteogenic differentiation confirmed by real-time PCR and alizarin red S methods. Bone healing has significantly occurred in defects treated with OE-MSCs encapsulated hydrogels in vivo. As a result, OE-MSCs with suitable carriers could be used as an appropriate cell source to address clinical bone complications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据